# Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

> **NCT03121677** · PHASE1 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 4 (actual)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** Personalized tumor vaccine
- **DRUG:** Poly ICLC
- **BIOLOGICAL:** Nivolumab
- **PROCEDURE:** Peripheral blood draws
- **PROCEDURE:** Leukapheresis
- **BIOLOGICAL:** Rituximab
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT03121677
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-16
- **Primary completion:** 2020-09-24
- **Final completion:** 2023-08-07
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Vaccine manufacturing has been suspended
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03121677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03121677, "Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03121677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*